Calamos Advisors LLC Castle Biosciences Inc Transaction History

Calamos Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 24, 2022	BUY	$22.51 - $34.32 $875,098 - $1.33 Million	38,876 New	38,876 $1.01 Million
Q4 2021 Feb 01, 2022	SELL	$39.06 - $67.58 $5.16 Million - $8.92 Million	-131,984 Closed	0 $0
Q3 2021 Oct 26, 2021	BUY	$60.13 - $77.6 $1.04 Million - $1.35 Million	17,377 Added 15.16%	131,984 $8.78 Million
Q2 2021 Jul 22, 2021	BUY	$50.07 - $76.78 $442,919 - $679,195	8,846 Added 8.36%	114,607 $8.41 Million
Q1 2021 Apr 12, 2021	SELL	$58.92 - $97.33 $2.42 Million - $4 Million	-41,075 Reduced 27.97%	105,761 $7.24 Million

Q4 2020 Jan 27, 2021	SELL	$43.6 - $73.05 $207,361 - $347,425	-4,756 Reduced 3.14%	146,836 $9.86 Million
Q3 2020 Oct 26, 2020	BUY	$38.47 - $52.03 $1.12 Million - $1.52 Million	29,207 Added 23.86%	151,592 $7.8 Million
Q2 2020 Jul 27, 2020	BUY	$27.28 - $43.01 $946,097 - $1.49 Million	34,681 Added 39.54%	122,385 $4.61 Million
Q1 2020 Apr 28, 2020	SELL	$23.08 - $35.53 $341,330 - $525,453	-14,789 Reduced 14.43%	87,704 $2.61 Million
Q4 2019 Jan 15, 2020	BUY	$15.74 - $35.04 $1.12 Million - $2.48 Million	70,845 Added 223.85%	102,493 $3.52 Million
Q3 2019 Oct 21, 2019	BUY	$18.09 - $27.92 $572,512 - $883,612	31,648 New	31,648 $572,000

162

25.3M

82.2K

150K

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $559M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

Get notified when there are updates to the investment portfolio of Calamos Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Calamos Advisors LLC with notifications on news.